Cohort Studyhigh evidence
Plasma infrared molecular fingerprinting stratifies residual risk in coronary artery disease and reflects clonal haematopoiesis-associated biology.
European heart journal·July 29, 2026·PMID 42522903
Why it mattersResidual cardiovascular risk in CAD patients remains high despite optimal secondary prevention, and current risk scores have limited predictive power. Plasma IMF offers a rapid, low-cost, sequencing-free tool that improves mortality risk discrimination and captures CHIP-associated biology, potentially enabling more precise risk stratification and targeted trial enrollment.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled